NCT06653725RecruitingPhase 2
Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure
Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure. A Randomized Clinical Trial (KETO-AHF)
Source: ClinicalTrials.gov · Last updated 5 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a multicenter, randomized, double-blind, placebo-controlled trial to investigate the clinical efficacy of treatment with exogenous dietary ketone supplement containing 1,3-butanediol in patients hospitalized with acute heart failure (AHF), potentially leading to better clinical outcomes.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 21 Oct 2024
- Start date
- 20 Mar 2025
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- Aarhus University Hospital
- Diseases
- Heart failure
- NCT number
- NCT06653725
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 250
- From 20 Mar 2025 to the primary completion date, 1 Nov 2027
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cardiogenic shock in INTERMACS level 1 or 2 (i.e. unstable hemodynamics despite inotropic/vasopressor therapy)
- Very severe lung disease and/or treatment with continuous home oxygen therapy
Other illness
- Current hospitalization for AHF triggered by significant arrhythmia (atrial fibrillation/flutter with sustained ventricular response \>110 beats per minute, clinically significant bradycardia, or sustained ventricular tachycardia)
- Recent cardiac surgery within 3 days
- Ongoing severe infection or sepsis, severe anemia, acute exacerbation of chronic obstructive pulmonary disease, pulmonary embolism, or cerebrovascular accident
- Significant primary valvular disease (hemodynamically severe uncorrected primary cardiac valvular disease)
- Planned implantation of a cardiac resynchronization therapy device
- Known obstructive hypertrophic cardiomyopathy, congenital heart disease, acute mechanical cause of acute heart failure (e.g., papillary muscular rupture), acute myocarditis, or constrictive pericarditis according to the treating physician
- Type 1 diabetes
- Advanced liver disease (Child-Pugh class C)
- Dementia or other cognitive disorder making the patient unable to give informed consent
- Significant gastrointestinal disease (i.e. severe inflammatory bowel disease or gastric ulcer)
- Awaiting cardiac transplantation
- Major comorbidity, medical condition, or health issue that, according to the investigator's judgment, would hinder the participant's capacity to engage in or successfully finish the study
Lab values
- eGFR \<15 mL/min/1.73 m2 during current hospitalization (unless ongoing continuous renal replacement therapy) or recurring dialysis
Other
- Likelihood or current use of mechanical circulatory support
- Pregnancy or breastfeeding
- Inability to intake oral substances or severe dysphagia
- Adherent to a ketogenic diet within 30 days of enrollment
Criteria the registry did not label
- The study will enroll adult patients (≥18 years) admitted with AHF as the primary diagnosis, meeting all the following criteria:
- Documented new or worsening symptoms due to heart failure with at least one of the following: persistent dyspnea at rest or with minimal exertion, or fatigue.
- Objective evidence of worsening heart failure, consisting of at least two physical examination findings consistent with fluid retention and/or end-organ hypoperfusion or one physical examination finding and at least one laboratory criterion:
- Physical examination findings considered to be due to heart failure, including new or worsened: i. Peripheral edema ii. Increasing abdominal distention or ascites (in the absence of primary hepatic disease) iii. Pulmonary rales/crackles/crepitations iv. Increased jugular venous pressure and/or hepatojugular reflux v. S3 gallop vi. Clinically significant or rapid weight gain thought to be related to fluid retention b) Laboratory evidence of worsening HF, if obtained within 24 hours of presentation, including: i. Increased B-type natriuretic peptide (BNP) / N-terminal pro-BNP (NT-proBNP) concentrations consistent with decompensation of heart failure. In patients with chronically elevated natriuretic peptides, an increase of \>30% above baseline should be noted.
- Radiological evidence of pulmonary congestion iii. Echocardiographic criteria include: Dilated inferior vena cava with minimal collapse on inspiration; decreased left ventricular outflow tract (LVOT) minute stroke distance (velocity time integral \[VTI\]); septal or lateral E/e' \>15 or \>12, respectively; D-dominant pulmonary venous inflow pattern.
- Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure ≥18 mmHg, central venous pressure ≥12 mmHg, or a cardiac index \<2.2 L/min/m2
- Treatment with at least 40 mg of intravenous furosemide or its equivalent and/or intravenous vasoactive drugs and/or inotropic drugs.
- An LVEF of ≤35% is required, measured during the present hospitalization.
- Participants must present with elevated levels of natriuretic peptides, specifically NT-proBNP ≥600 pg/mL or BNP ≥150 pg/mL. For those in atrial fibrillation at the time of inclusion, NT-proBNP levels must be ≥900 pg/mL or BNP ≥225 pg/mL.
- The enrollment window extends to the first five days of the hospital stay.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Cardiology, Aalborg University Hospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Not yet recruiting |
| Department of Cardiology, Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus N | Denmark | Recruiting |
| Department of Cardiology, Herlev-Gentofte Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
| Department of Cardiology, Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Not yet recruiting |
| Department of Cardiology, Gødstrup Hospital, Herning, Denmark Coordinator of this site? Confirm its status | Herning | Denmark | Recruiting |
| Department of Cardiology, Copenhagen University Hospital - Amager and Hvidovre Hospital Coordinator of this site? Confirm its status | Hvidovre | Denmark | Recruiting |
| Department of Cardiology, Odense University Hospital Coordinator of this site? Confirm its status | Odense | Denmark | Not yet recruiting |
| Department of Cardiology, Viborg Hospital Coordinator of this site? Confirm its status | Viborg | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.